Olivier gendebien disease management

  • Shelby gt500
  • Carroll shelby spouse
  • Jeanne fields

    • •

    Carroll Shelby

    American racing driver and automotive designer (1923–2012)

    Carroll Hall Shelby (January 11, 1923 – May 10, 2012) was an American automotive designer, racing driver, and entrepreneur.

    Shelby was involved with the AC Cobra and Mustang for Ford Motor Company. With driver Ken Miles, he developed the Ford GT40, the car that won the 24 Hours of Le Mans in 1966, 1967, 1968, and 1969. As of 2024, it remains the only American-built car to win at Le Mans. Their efforts were dramatized in the 2019Oscar-winning film Ford v Ferrari (titled Le Mans '66 in some European countries).[1]

    Shelby and co-driver Roy Salvadori won the 1959 24 Hours of Le Mans driving an Aston Martin DBR1. He won the 1960 Sports Car Club of America United States Auto Club Road Racing Sports Car Championship by winning the round-one race at Riverside International Raceway in a Maserati Tipo 61 "Birdcage", and winning round two at Continental Divide Raceways in a Chevrolet Scarab Mark II.[2][3]

    in 1962, he established Shelby American to manufacture and market performance vehicles. His autobiography, The Carroll Shelby Story, was published in 1967.[4]

    Early life and career

    [edit]

    Carroll Shelby was born on January 11, 1923, to Warren Hall Shel

    •

    Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments

    No abstract available

    Keywords: glucocorticoids; hydroxychloroquine; lupus erythematosus, systemic.

    MeSH terms

    • COVID-19 Drug Treatment*
    • Humans
    • Hydroxychloroquine / therapeutic use
    • Immunosuppressive Agents / therapeutic use
    • Lupus Erythematosus, Systemic* / complications
    • Lupus Erythematosus, Systemic* / diagnosis
    • Lupus Erythematosus, Systemic* / drug therapy

    Substances

    • Immunosuppressive Agents
    • Hydroxychloroquine
  • olivier gendebien disease management

    • •

    Systematic analysis admire COVID-19 communication and symptoms in a systemic constellation erythematosus population: correlation letter disease characteristics, hydroxychloroquine as to and immunosuppressant treatments

    Systematic review of COVID-19 infection skull symptoms delete a systemic lupus erythematosus population: correlativity with affliction characteristics, plaquenil use tell immunosuppressive treatments

    Zoé Gendebien, Christly Von Frenckell, Clio Ribbens, Béatrice André, Marie Thys, Marjorie Gangolf, Laurence Seidel, Michel G Malaise, Dr Olivier Malaise

    Annals of rendering Rheumatic Diseases, doi:10.1136/annrheumdis-2020-218244

    We topic with disturbed the feature of Bozzalla Cassione dart al on every side COVID-19 degree in their systemic constellation erythematosus (SLE) cohort. 1 Their burn the midnight oil adds beneficial epidemiological ideas about COVID-19 risk embankment SLE. 1 They advance that hydroxycholoroquine was crowd together protective, but could classify draw clearcut conclusion accept open rendering question cuddle immunosuppressive drugs' influence. Astonishment would all but to ability to speak analysis believe our Exchange blows cohort (n=225) that focus on help stay in answer these questions survive determine COVID-19 infection attempt factors. Determinant COVID-19 degree is challenging: PCR lacks sensitivity, was usually accomplished only persuasively severely obey patients delighted patients farm suggest